Abstract
We previously reported that peripheral blood mononuclear cells from HLA-DRB1*0101 Japanese patients with rheumatoid arthritis (RA) were highly reactive to 256-271 peptide of type II collagen (CII). In this report, we tried to regulate the CII reactivity of T cells from RA patients with HLA-DRB1*0101 by altered peptide ligand (APL), which is a single amino acid substitution of the T-cell epitope on CII 256-271 peptide. Antagonistic activity of 21 APLs was assessed using three different T-cell lines. Results showed that 262 (G-->A) APL of CII 256-271 exhibited antagonistic activity in all T-cell lines and it was suggested that the application of CII APL might be a new therapeutic strategy in the regulation of RA.
MeSH terms
-
Amino Acid Sequence
-
Amino Acid Substitution
-
Arthritis, Rheumatoid / immunology*
-
Arthritis, Rheumatoid / metabolism
-
Arthritis, Rheumatoid / therapy*
-
Cell Division / immunology
-
Cell Line
-
Collagen Type II / genetics
-
Collagen Type II / metabolism
-
Collagen Type II / pharmacology*
-
HLA-A Antigens / genetics
-
HLA-DRB1 Chains
-
Humans
-
In Vitro Techniques
-
Ligands
-
Lymphocyte Activation / immunology
-
Molecular Sequence Data
-
Peptide Fragments / genetics
-
Peptide Fragments / metabolism
-
Peptide Fragments / pharmacology*
-
Receptors, Antigen, T-Cell / antagonists & inhibitors
-
Receptors, Antigen, T-Cell / immunology
-
T-Lymphocytes / cytology
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / metabolism
Substances
-
Collagen Type II
-
HLA-A Antigens
-
HLA-DRB1 Chains
-
HLA-DRB1*01:01 antigen
-
Ligands
-
Peptide Fragments
-
Receptors, Antigen, T-Cell